SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

Biohaven Underscores Depth Of Migraine Portfolio With Data From Nurtec ODT Long-Term Open Label Study And Phase 3 Zavegepant Trial At 64th Annual Scientific Meeting Of The American Headache Society

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data Late-breaking submissions showcase new data for Nurtec ODT in

Benzinga · 06/09/2022 07:31
  • 31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data
  • Late-breaking submissions showcase new data for Nurtec ODT in Chinese and Korean patients and patterns of medication utilization in adults using it as an acute and preventive treatment
  • Results from long-term studies of Nurtec ODT as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a 100% reduction
  • Other oral presentations included safety and efficacy of zavegepant nasal spray as an acute treatment of migraine and an analysis of placebo responses over time in oral migraine preventive trials